Mucosal Atomization Devices Global Market Report 2024

Mucosal atomization devices are designed to administer medication through the nostrils, ensuring reliable topical solution atomization across the nasal and oropharyngeal mucous membranes. These devices are particularly effective in delivering atomized medication to mucosal surfaces in the nasal, oral, laryngeal, tracheal, and lung regions.

The primary types of mucosal atomization devices include nasal atomization devices, fibre-optic atomization devices, laryngotracheal atomization devices, and bottle atomizer devices. Nasal atomization devices provide a painless and safe method for swiftly delivering fast-acting drugs that efficiently penetrate mucosal membranes and enter the bloodstream. Various mucosal atomization device technologies include gas-propelled atomization devices and electrical atomization devices. These devices find application in diverse healthcare settings, including hospitals, ambulatory surgical centers, and specialized clinics.

The mucosal atomization devices market research report is one of a series of new reports that provides mucosal atomization devices market statistics, including mucosal atomization devices industry global market size, regional shares, competitors with an mucosal atomization devices market share, detailed mucosal atomization devices market segments, market trends and opportunities, and any further data you may need to thrive in the mucosal atomization devices industry. This mucosal atomization devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mucosal atomization devices market size has grown strongly in recent years. It will grow from $0.79 billion in 2023 to $0.87 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth observed in the historical period can be attributed to factors such as the application of mucosal atomization devices in emergency medicine, anesthesia procedures, pediatric care, pain management, and dental procedures.

The mucosal atomization devices market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to factors such as the use of mucosal atomization devices in the treatment of chronic diseases, the expansion of telemedicine practices, the adoption of precision medicine, the application in cosmetic procedures, enhancing patient comfort, and potential use in autonomous vehicles. Key trends expected during this period include the promotion of sustainable and eco-friendly practices in the industry, the implementation of digital mortuary management systems, the introduction of green burial options, the rise of remote viewing and streaming services for funeral events, and the emergence of hybrid funeral services that integrate traditional and modern elements.

The growth of the mucosal atomization devices market is driven by the increasing prevalence of allergic rhinitis worldwide. Allergic rhinitis, characterized by symptoms affecting the nose due to exposure to allergens like pollen, dust, or animal dander, prompts the use of mucosal atomization devices for chronic rhinosinusitis treatment, delivering budesonide as a topical nasal steroid spray. Seasonal allergic rhinitis, commonly known as hay fever, is a prevalent allergic condition, affecting approximately 7.7% of adults and 7.2% of children in the United States, as reported in the Allergy Capital Report 2022. Consequently, the rising incidence of allergic rhinitis globally contributes to the growth of the mucosal atomization devices market.

The anticipated growth in the elderly population is set to propel the mucosal atomization device market forward. Defined as individuals aged 65 and above, the elderly population is expected to play a significant role in driving the demand for mucosal atomization devices. With aging, susceptibility to chronic conditions such as allergic rhinitis and sinusitis increases, necessitating the use of mucosal atomization devices for treatment. Data from America's Health Rankings indicates that in the United States, over 56 million adults aged 65 and above constitute around 16.9% of the total population. The projection of more than 73.1 million older individuals by 2030, as the baby boomer generation ages, further emphasizes the role of the elderly population in fueling the mucosal atomization device market.

Strategic partnerships emerge as a key trend gaining popularity in the mucosal atomization devices market. Leading companies in this sector are increasingly entering partnerships to strengthen their market positions. For instance, Pulmodyne Inc., a US-based provider of drug atomization delivery, collaborated with Alcove Manufacturing and Distribution Inc., a UK-based company, in October 2021. Through this partnership, the EZ-Spray Atomization System is set to be distributed by Pulmodyne, leveraging its existing channels. The collaboration aims not only to enhance distribution but also to drive innovation in the industry, allowing both seasoned companies to optimize product designs promptly.

Major companies in the mucosal atomization device market are adopting strategic partnerships to facilitate distribution expansion, integrate manufacturing capabilities, and jointly develop new atomization technologies. In another example from October 2021, Pulmodyne, Inc. and Alcove Manufacturing and Distribution, Inc. announced their partnership, focusing on the distribution of the EZ-Spray Atomization System and fostering innovation within the industry. This collaborative effort enables the two experienced companies to quickly optimize product designs and advance the field.

In March 2022, Kurve Technology Inc., a US-based company specializing in the development of liquid drug delivery devices, merged with Savile Therapeutics Inc. This merger provides Kurve Technology access to the assets of Savile Therapeutics Inc., fostering further growth and expansion. Savile Therapeutics Inc. is a US-based medical device company.

Major companies operating in the mucosal atomization devices market include Teleflex Incorporated, DeVilbiss Healthcare LLC, Becton Dickinson and Company, Cook Medical LLC, Medica Holdings LLC, Life-Assist Inc., Pulmodyne Inc., Alcove Manufacturing and Distribution Inc., LMA North America Inc., Medline Industries Inc., Medtronic PLC, Smiths Medical Inc., Vyaire Medical Inc., Westmed Inc., Mercury Medical, SunMed LLC, Salter Labs, Armstrong Medical Industries Inc., VBM Medizintechnik GmbH, Intersurgical Ltd., Flexicare Medical Limited, Medovations Inc., Medis Medical Imaging Systems, Medisize BV, Atom Medical Corporation, BLS Systems Limited, Bona Pharma Inc., Central Admixture Pharmacy Services Inc., Dali Medical Devices Co. Ltd., Dynarex Corporation

North America was the largest region in the mucosal atomization devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mucosal atomization devices market growth report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the mucosal atomization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The mucosal atomization devices market consists of sales of 3cc Syringe and VetJet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.